Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2022 | T-cell response following COVID-19 vaccination in MS patients under treatment

João José Cerqueira, MD, PhD, University of Minho, Braga, Portugal, reports the findings from a study evaluating the T-cell response following COVID-19 vaccination in patients with multiple sclerosis (MS) under disease-modifying treatment. COVACIMS is an ongoing prospective Portuguese multicentre cohort study assessing the immunogenicity of COVID-19 vaccination in MS patients, including T-cell response quantification. In the cohort evaluated, it was found that most treatments don’t alter the T-cell response to COVID-19 vaccines, only fingolimod-treated patients had decreased T-cell response rate. Additionally, the vaccine regimen doesn’t seem to affect the T-cell response since patients with only primary vaccination and those with boosters showed similar results. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


JC has received consultancy fees from Biogen, Roche, Novartis, Almirall, Janssen, Bristol-Myers-Squibb, Merck and Zambon; and research grants from Biogen, Roche, Merck and Novartis, as well as the Portuguese Foundation for Science and Technology and Clinical Academic Centre Braga.